Recent data shows a 92.9% five-year survival rate for localized kidney cancer. For metastatic disease, that figure drops sharply to 15.1%. This article details the specific variables that define a patient's prognosis.
Key Takeaways
- For patients under 45, localized kidney cancer 5-year survival is 98.3% (SEER)
- The 5-year relative survival rate for kidney and renal pelvis cancer overall is 76.4% for patients diagnosed between 2013-2019
- High Fuhrman grade associated with 20% lower 5-year survival
- SEER data shows 5-year survival for localized kidney cancer at 92.9% (2013-2019)
- Nephrectomy patients have 5-year survival of 85% for early stage
Many kidney cancer patients live long after diagnosis, with survival rates steadily improving over time.
Related reading
01 · Category
Demographic Survival Variations20 stats
01
For patients under 45, localized kidney cancer 5-year survival is 98.3% (SEER)
02
Males have 5-year kidney cancer survival of 75.2% vs 77.9% for females (SEER 2013-2019)
03
Black patients 5-year survival 73.6% vs 77.1% for White (SEER)
04
Age 65-74 group has 5-year survival of 75.8% for kidney cancer
05
Women under 65 have 84% 5-year survival for localized RCC
06
Hispanic patients 5-year survival 78.9% (SEER)
07
Elderly >80 years 5-year survival drops to 47.2%
08
Asian/Pacific Islander 5-year survival 80.7% (SEER)
09
Rural residents have 2% lower 5-year survival than urban
10
Smokers have 15% lower 5-year survival for RCC vs non-smokers
11
Age <50 localized stage 5-year survival 97%
12
Female gender advantage 5-year survival +2.7% (SEER)
13
American Indian 5-year survival 72.1% (SEER)
14
45-64 age group 5-year survival 82.5%
15
Obese patients BMI>30 have 10% worse survival
16
Socioeconomic low quintile survival 5% lower
17
Male smokers 5-year survival 70% vs 80% non-smokers
18
Urban vs rural survival gap 3.2% at 5 years
19
Comorbid diabetes reduces OS by 25%
20
Hypertension comorbidity 5-year survival 74%
Interpretation
Demographic Survival Variations Interpretation
These statistics reveal a clear, sobering hierarchy: while youth and early detection offer near-certain victory, the battle against kidney cancer is disproportionately harder for the elderly, smokers, those with comorbidities, and patients facing systemic disadvantages rooted in race, income, and geography.
02 · Category
Overall Survival Statistics16 stats
01
The 5-year relative survival rate for kidney and renal pelvis cancer overall is 76.4% for patients diagnosed between 2013-2019
02
The 10-year relative survival rate for kidney cancer is approximately 57% based on SEER data from 2012-2018
03
In the US, the 5-year survival rate for kidney cancer improved from 64% in the 1970s to 76% in recent years
04
European age-standardized 5-year survival for kidney cancer is 60.3% (2010-2014 data)
05
In England, the 5-year net survival for kidney cancer is 56.6% for patients diagnosed 2016-2020
06
Australian 5-year relative survival for kidney cancer diagnosed 2014-2018 is 72%
07
Japanese 5-year survival rate for renal cell carcinoma is 81.9% (2006-2008 cohort)
08
In China, 5-year overall survival for RCC is 38.7% from a multi-center study 2005-2014
09
Canadian 5-year net survival for kidney cancer 2014-2018 is 68%
10
Global 5-year survival for kidney cancer varies from 36% in low-income to 74% in high-income countries (CONCORD-3)
11
Clear cell subtype 5-year survival 77% vs 62% papillary (SEER)
12
5-year survival for chromophobe RCC is 89%
13
Collecting duct carcinoma 5-year survival <20%
14
Unclassified RCC 5-year survival 68%
15
Median OS for advanced non-clear cell RCC 24.8 months with cabozantinib
16
5-year survival in MSKCC favorable risk mRCC 32%
Interpretation
Overall Survival Statistics Interpretation
While the odds of surviving kidney cancer have improved dramatically, your specific prognosis is a complex cocktail shaken with your tumor's personality, your country's healthcare system, and a sobering dash of global inequality.
03 · Category
Risk Factor and Prognostic Survival Stats19 stats
01
High Fuhrman grade associated with 20% lower 5-year survival
02
Sarcomatoid differentiation reduces median OS to 10 months
03
Elevated LDH >1.5x ULN predicts median OS 4 months in mRCC
04
IMDC poor risk mRCC median OS 8.8 months
05
Neutrophil-lymphocyte ratio >4 linked to 50% higher mortality risk
06
Tumor size >7cm reduces 5-year recurrence-free survival to 60%
07
Positive surgical margins decrease 5-year survival by 15%
08
ECOG PS >=2 halves median OS in advanced RCC
09
Low hemoglobin prognosticates poorer survival in MSKCC model
10
Lymphovascular invasion predicts 40% recurrence risk at 5 years
11
Rhabdoid features median OS 7 months
12
Hypercalcemia in mRCC median OS 4.6 months
13
IMDC intermediate risk median OS 20.6 months
14
Platelet-lymphocyte ratio >193 worse OS HR 2.1
15
Necrosis >10% tumor volume 5-year RFS 70%
16
Perinephric fat invasion 5-year CSS 75%
17
Anemia <LLN OS HR 1.8 in advanced disease
18
Time from diagnosis to treatment >60 days worse survival
19
MSKCC favorable risk 5-year survival 60%
Interpretation
Risk Factor and Prognostic Survival Stats Interpretation
This grim roll call of tumor treachery, from rebellious cells to hijacked blood labs, paints a stark portrait of kidney cancer as a formidable foe that weaponizes everything from its own architecture to the body's distress signals to undermine survival.
More related reading
04 · Category
Stage-Specific Survival Rates19 stats
01
SEER data shows 5-year survival for localized kidney cancer at 92.9% (2013-2019)
02
5-year survival for regional stage kidney cancer is 71.4% per SEER 2013-2019
03
Distant metastatic kidney cancer has 5-year survival of 15.1% (SEER 2013-2019)
04
Stage I RCC 5-year cancer-specific survival is 96.4% post-surgery
05
Stage II kidney cancer 5-year survival is 87% according to ACS
06
Stage III RCC 5-year overall survival is 64% in surgical cohorts
07
Stage IV metastatic RCC median overall survival is 18 months with modern therapies
08
T1a tumors have 5-year survival >98%
09
T3 RCC stage 5-year survival is 53%
10
Localized disease (T1-2N0M0) 10-year survival is 81.5%
11
Stage I-II 5-year survival 93% per ACS data
12
Stage III 5-year survival 60% (ACS)
13
Stage IV 5-year survival 12% (ACS)
14
pT1N0M0 10-year CSS 94.2%
15
N1 disease 5-year survival 45%
16
M1 at diagnosis median OS 14 months pre-immunotherapy era
17
T1b 5-year RFS 85%
18
Lymph node positive stage 5-year OS 40%
19
Oligometastatic (≤3 sites) 5-year survival 30%
Interpretation
Stage-Specific Survival Rates Interpretation
The data paints a brutally clear picture: kidney cancer is often curable if caught early and confined, but becomes a fierce and formidable adversary once it gains ground, with survival odds plummeting as it advances.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Kidney Cancer Survival Statistics. Gitnux. https://gitnux.org/kidney-cancer-survival-statistics
MLA
Marie Larsen. "Kidney Cancer Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/kidney-cancer-survival-statistics.
Chicago
Marie Larsen. 2026. "Kidney Cancer Survival Statistics." Gitnux. https://gitnux.org/kidney-cancer-survival-statistics.
Sources & references
8 datasets cited across this report · attribution is report-level